For the last quarter-century, the Washington-based political class has chosen not to think much about life-saving drugs. Instead, we’ve been subjected to an unending debate over national health insurance: first Clintoncare, and then Obamacare. Health insurance is important, of course. But health itself is more important.
Trump has been specific on two policy ideas, both of which are anathema to the pharmaceutical companies and their traditional Republican allies.
The first idea is reimportation; the second is price-negotiation.
No comments:
Post a Comment